共 28 条
- [1] A PHASE 1/2 STUDY OF ASP1570 IN PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WHO HAVE PROGRESSED ON, OR ARE INELIGIBLE FOR, ALL AVAILABLE STANDARD THERAPIESJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A786 - A786Patel, ManishPark, DavidTarantolo, StefanoDowlati, AfshinOlson, DanielKaneko, YuichiroTang, MeiSoukharev, SergueiTakizawa, MasaomiOkada, YoheiFredericks, ChristineSmith, DerekFlegel, TeresaWatanabe, TsubasaLee, SueLuke, Jason
- [2] Phase I/II trial of ASP1570, a novel diacylglycerol kinase z inhibitor, in patients with advanced solid tumorsANNALS OF ONCOLOGY, 2024, 35 : S683 - S683Olson, D.Dowlati, A.Luke, J. J.Mckean, M.Yoshida, T.Park, D.Kitano, S.Barve, M.Kaneko, Y.Koelsch, G.Soukharev, S.Takeshita, S.Alsharif, N.Hashemi, N.Patel, M. R.
- [3] SKB264 ADC: A first-in-human study of SKB264 in patients with locally advanced unresectable/metastatic solid tumors who are refractory to available standard therapies.JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Liu, YonghengLian, WeiZhao, XiDiao, YinaXu, JianXiao, LiangQing, YanXue, TongtongWang, Jingyi
- [4] Phase 1/2 study of FMC-376 an oral KRAS G12C dual inhibitor in participants with locally advanced unresectable or metastatic solid tumors (PROSPER).JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Keating, Anne TheresePapadopoulos, Kyriakos P.Hloros, EleniSpira, Alexander I.McKean, William BennionKrivoshik, Andrew Peter
- [5] A phase 1/2 study of a novel IL-2 cytokine, NKTR-214, and nivolumab in patients with select locally advanced or metastatic solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Diab, AdiTannir, Nizar M.Bernatchez, ChantaleHaymaker, Cara L.Bentebibel, Salah E.Curti, Brendan D.Wong, Michael K. K.Gergel, IvanTagliaferri, Mary AnnZalevsky, JonathanHoch, UteAung, SandraImperiale, MichaelCho, Daniel C.Tykodi, Scott S.Puzanov, IgorKluger, Harriet M.Hurwitz, Michael E.Hwu, PatrickSznol, Mario
- [6] Lerociclib plus fulvestrant in patients with HR+/HER2-locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trialNATURE COMMUNICATIONS, 2025, 16 (01)Xu, BingheZhang, QingyuanLuo, YangTong, ZhongshengSun, TaoShan, ChangpingLiu, XinlanYao, YuminZhao, BingWang, ShusenZeng, XiaohuaHu, ChangluYan, XiWang, XiaojiaJia, HongyanChen, ZhendongQiu, FumingWu, XinhongZhang, DeyongLi, Tong
- [7] TRIAL IN PROGRESS: PHASE 1 FIRST-IN-HUMAN STUDY OF XL092 ADMINISTERED ALONE OR IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORSJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A544 - A544Patnaik, AmitaSubbiah, VivekShapiro, GeoffreyPal, SumantaAgarwal, NeerajWentzel, KristopherLi, JingMcIlvaine, ElizabethWaldes, JanaCha, EdwardTadjalli-Mehr, KeyvanSharma, Manish
- [8] Phase 1/2 study of PRO1184, a novel folate receptor alpha-directed antibody-drug conjugate, in patients with locally advanced and/or metastatic solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Call, Justin A.Orr, Douglas W.Anderson, Ian ChurchillRichardson, Debra L.Chen, ZhuMa, SharonHunder, Naomi N. H.Hamilton, Erika P.
- [9] Phase 1/2 study of PRO1184, a novel folate receptor alpha-directed antibody-drug conjugate, in patients with locally advanced and/or metastatic solid tumorsCANCER RESEARCH, 2023, 83 (08)Call, JustinOrr, DouglasAnderson, IanRichardson, Debra L.Chen, ZhuMa, SharonHunder, Naomi N.Hamilton, Erika
- [10] NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting Nectin-4 in participants with advanced or metastatic urothelial carcinoma or other solid tumors (Trial in Progress)EUROPEAN JOURNAL OF CANCER, 2024, 211 : S66 - S66Baldini, C.Patnaik, A.Lakhani, N.Call, J.Galsky, M.Garmezy, B.Wei, A.Carter, L.Powles, T.Siefker-Radtke, A.O'Donnell, P. H.Kitano, S.Castellano, D. E.Shinde, R.Joshua, A. M.Balbas, M.Han, H.Chang, A. E.Gao, X.Iyer, G.